Emiac Technologies IPO
The SME IPO of Emiac Technologies, which opened on Friday, will resume its public bidding in the coming week. The issue closes on Wednesday, April 8. The issue was subscribed 33% on the opening day.The company plans to raise Rs 31.75 crore through the issue which is entirely a fresh issuance of equity shares. Ahead of the opening, the grey market premium (GMP) indicated a muted listing.
The company has set the price band at Rs 93–98 per share and investors can apply for a minimum of 1 lot which comprises 1,200 equity shares amounting to Rs 1,17,600.
In the book-building issue, the company will issue 32.40 lakh equity shares aggregating up to Rs 31.75 crore.
Mainboard listings
CMPDI IPO
Central Mine Planning will get listed on the exchanges on Monday, March 30. Ahead of its listing, the company’s shares were commanding a grey market premium (GMP) of Rs 6-7 over the upper price band of Rs 172. The stock is expected to list around Rs 179, implying a gain of over 4%.
The Rs 1,842 crore IPO CMPDI managed to sail through on the final day of bidding. By the end of Day 3, the issue was fully subscribed at 1.05 times the 7.97 crore shares on offer. The issue received over 8.36 crore share bids. Demand was mainly driven by Qualified Institutional Buyers (QIBs), who subscribed the IPO 3.48 times their quota, while Retail Individual Investors (RIIs) showed muted interest at just 33%. The non-institutional investors’ (NII) quota also failed to get fully booked, managing only 35% subscription.
Sai Parenteral’s IPO
The mainboard issue that closed on Friday, is expected to make its market debut on Thursday, April 2. Its GMP suggests a flat listing at Rs 392.
The issue was subscribed 1.05 times over a three-day bidding period. It received over 78.80 lakh share bids against 75,22,486 equity shares available for booking.
The demand was mainly driven by non-institutional investors’ (NII) who subscribed the issue 2.36 times. Qualified Institutional Buyers (QIBs) subscribed the IPO 1.71 times their quota, while Retail Individual Investors (RIIs) hardly showed any interest, subscribing just 12% shares of the available quota.
Powerica IPO
This mainboard issue also ended on Friday. It is expected to make its market debut on Thursday, April 2. Its GMP suggests a muted listing at Rs 395, implying a listing premium of around 1%.
The issue was overall subscribed 1.45 times over a three-day bidding period. The demand was mainly driven by Qualified Institutional Buyers (QIBs) who subscribed the IPO 4.5 times of their quota, while Retail Individual Investors (RIIs) hardly showed any interest, subscribing just 14% shares of the available quota.
The company planned to raise Rs 1,100 crore through the issue which is a combination of an offer for sale (OFS) and issuance of fresh equity. The company has set the price band at Rs 375–395 per share and retail investors can make applications for a minimum of 1 lot which comprises 37 equity shares amounting to Rs 14,615.
Amir Chand Jagdish Kumar IPO
The Rs 440 crore IPO of Amir Chand Jagdish Kumar Exports ended on Friday. The offering was subscribed 3.41 times against the total 1.89 crore shares on offer.
In the grey market, the IPO is commanding a premium of around 1.2%, or roughly Rs 3 above the issue price of Rs 212, suggesting a likely listing price near Rs 215.
This IPO is entirely a fresh issue of 2.08 crore shares, aiming to raise Rs 440 crore. The company is set to list on both the NSE and BSE, with a tentative listing date of April 2, 2026.
SME listings
The SME issue Speciality Medicines which closed on March 24 will list on Monday. The stock is expected to list flat on the BSE SME.
Tipco Engineering India IPO, ended on March 25. The stock will list on Wednesday April 1 on the BSE SME platform. The GMP revealed no listing gains.
Highness Microelectronics IPO ended on Friday. Its GMP suggests a listing at a 20% premium over the issue price of Rs 120. The estimated listing price is Rs 145.
(Disclaimer: The recommendations, suggestions, views, and opinions given by the experts are their own. These do not represent the views of The Economic Times.)